0000000001274792

AUTHOR

Pascal Foucher

showing 6 related works from this author

Towards a new methodology of studying flints, by using GIS and a georeferenced database in the South of France

2014

International audience; Towards a new methodology of studying flints, by using GIS and a georeferenced database in the South of France

SouthTowards[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistorygeoreferenced[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and PrehistorystudyingmethodologyFranceflintsdatabaseusing
researchProduct

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

2020

Abstract Introduction Non-small-cell lung cancer (NSCLC) is one of the most common and deadly cancers. Several molecular drivers of oncogene addiction are now known to be strong predictive biomarkers for target therapies. Advances in large Next Generation Sequencing (LNGS) have improved the ability to detect potentially targetable mutations. However, the integration of LNGS into clinical management in an individualized manner remains challenging. Methods In this single-center observational study we included all patients with advanced NSCLC who underwent LNGS. Somatic and germline exome analysis was performed with a restriction on 323 cancer related genes. Variants were classified and Molecu…

Pulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentGermlineTargeted therapyInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansExomeLung cancerExomeLungbusiness.industryHigh-Throughput Nucleotide SequencingOncogenesPrecision medicinemedicine.diseaseCancer related genesmedicine.anatomical_structureOncologyMutationNon small cellbusinessLung cancer (Amsterdam, Netherlands)
researchProduct

Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung canc…

2018

e24184Background: Multiple EGFR tyrosine kinase inhibitors (TKIs) are approved for treatment of NSCLC harboring EGFR activating mutations or secondary TKIs resistant mutation. We evaluate a new PET...

Cancer Research[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingnon-small cell lung cancer (NSCLC)[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicinemedicineIn patientComputingMilieux_MISCELLANEOUSmedicine.diagnostic_testbusiness.industryPet imagingmedicine.diseaseEGFR Tyrosine Kinase Inhibitorsrespiratory tract diseases3. Good health[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingOncologyEgfr mutationPositron emission tomography030220 oncology & carcinogenesisMutation (genetic algorithm)Cancer researchbusiness030215 immunology
researchProduct

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

2020

Abstract Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma…

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyendocrine system diseases[SDV.CAN]Life Sciences [q-bio]/Cancermedicine.disease_causeNSCLClcsh:RC254-28203 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerNon-small cell lung cancerInternal medicinemedicineOverall survivalNon–small cell lung cancerStage (cooking)neoplasms030304 developmental biology0303 health sciencesMutationTransition (genetics)business.industryKRAS mutationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisConfidence intervaldigestive system diseases3. Good healthrespiratory tract diseasesOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleKRASbusinessKras mutation
researchProduct

A map and a database for flint bearing formations in Southern France: a tool for Petroarchaeology

2013

[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistorypréhistoire
researchProduct

Une carte et une base de données pour les formations à silex dans le Sud de la France.

2012

Programme et résumés, page 139; Une carte est en cours de réalisation pour figurer les principales formations contenant des silex dans le Sud de la France. Elle est le fruit d'une collaboration entre des acteurs impliqués dans la problématique de caractérisation de la provenance des silex. Elle regroupe les résultats de leurs prospections systématiques ou ciblées dans cinq régions (Auvergne, Rhône-Alpes, Provence Alpes Côte-d'Azur, Aquitaine, Midi-Pyrénées). Elle intègre le dépouillement d'un nombre considérable de documents : - 529 cartes géologiques au 1/50 000 et leurs notices ; - Plus de 200 fiches issues de la base de données du sous-sol BSS du BRGM, qui permettent de visualiser des lo…

Silex[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistory[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and PrehistoryProvence Alpes Côte-d'Azur[SDU.STU] Sciences of the Universe [physics]/Earth SciencesAquitainecartographie[SDU.STU]Sciences of the Universe [physics]/Earth SciencesRhône-AlpesMidi-PyrénéesAuvergne
researchProduct